Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
8
×
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
gilead sciences
8
×
indiana blog main
indiana top stories
life sciences
national
8
×
national blog main
8
×
national top stories
new york blog main
new york top stories
novartis
8
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
abbvie
cancer
immunotherapy
startups
alzheimer's disease
biogen
cancer immunotherapy
clinical trials
deals
europe blog main
europe top stories
What
bio
roundup
acquisitions
ceo
drug
annual
biggest
covid
daniel
days
gilead
ipo
medicines
new
o’day
price
sciences
abbvie’s
activity
ahead
airport
albert
american
announced
apocalypse
approval
approvals
ash
beds
biofourmis
biogen
biogen’s
biopharmaceutical
blood
borne
bourla
bucks
build
buy
cancer
Language
unset
unknown
Current search:
biotech
×
novartis
×
" national blog main "
×
national
×
" gilead sciences "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More